OncoCyte (OCX) Investor Presentation - Slideshow

Company Mission and Growth Engines - Oncocyte's mission is to provide actionable answers at critical decision points across the cancer care continuum, improving patient outcomes by optimizing diagnosis and treatment[7] - Oncocyte focuses on high-value, unanswered clinical questions in lung cancer, representing a > $3 billion market opportunity[9] - DetermaIO™ is a novel molecular test assessing the tumor micro-environment (TME) to predict immunotherapy response, launched as Research Use Only (RUO)[9] - DetermaRx™ is the first and only molecular test identifying Non-Small Cell Lung Cancer (NSCLC) patients at high risk of recurrence post-surgery[9] DetermaRx and Lung Cancer - The global market for early-stage lung cancer testing is estimated at > $450 million, serving ~350,000 early-stage non-squamous NSCLC patient treatment decisions annually[21] - 30-50% of early-stage NSCLC patients recur after surgical resection[21] - In a study, 48% of NCCN "low Risk" patients were reclassified to high-risk by DetermaRx[37] - DetermaRx high-risk patients, upon treatment, had a Disease-Free Survival (DFS) of 92.8%[37] DetermaIO and Immunotherapy - The annual addressable testing market for IO therapy is ~$3 billion in the US alone[55] - Up to 55% of patients receiving IO therapy derive no benefit but are exposed to side effects, representing ~$60 billion in healthcare investment with no patient benefit by 2025[55] - In a study, DetermaIO showed a Hazard Ratio (HR) of 0.31 (95% CI 0.14 to 0.68; p=0.004) for Progression Free Survival (PFS) compared to PD-L1 and TMB in lung cancer[63] - In a TNBC study from MD Anderson, DetermaIO-positive patients were 4x more likely to respond than DetermaIO-negative patients (Odds Ratio 4.13, 95% CI 1.36 – 13.47, p<0.015)[65]